2025年5月28日 周三
Home > Archive>Volume 28, Issue 5, 2020 >452-455
PDF HTML XML Export Cite reminder
Relationship between anti-infective therapy and atherosclerosis
Author:
Affiliation:

1.Graduate School, North China University of Science and Technology, Tangshan, Hebei 063000;2.Graduate School, Hebei North University, Zhangjiakou, Hebei 075000;3.Geriatric Cardiology, Hebei General Hospital, Shijiazhuang, Hebei 050000, China)

Clc Number:

R5

  • Article
    • | |
  • Metrics
    • |
  • Reference [39]
    • | | | |
  • Comments
    Abstract:

    Many human and animal model studies have shown a link between infection and atherosclerosis. Infectious factors provide major stimuli for the development and progression of inflammation by causing changes in cells and molecules. Inflammation is an important mechanism of atherosclerosis. Infection can be divided into direct and indirect effects on atherosclerosis. From the current part of the experiment,the anti-infective treatment may have a positive effect on the formation of atherosclerosis. It can reduce the formation of atherosclerosis by reducing inflammatory stimuli and regulating cytokines. It introduces two hypotheses of infection burden and molecular mimicry. The possible mechanism of negative antibiotic test has guiding significance for further clinical and experimental research in the future.

    Reference
    [1] Liao CM, Lin CM.Life course effects of socioeconomic and life style factors on metabolic syndrome and 10-year risk of cardiovascular disease:a longitudinal study in Taiwan Adults.Int J Environ Res Public Health, 8,5(10).DOI:10.3390/ijerph15102178
    [2] Geovanini GR, Libby P.Atherosclerosis and inflammation:overview and updates.Clin Sci (Lond), 8,2(12):1243-1252.
    [3] Da SR.Influence of inflammation and atherosclerosis in atrial fibrillation.Curr Atheroscler Rep, 7,9(1):2.
    [4] Tousoulis D, Oikonomou E, Economou EK, et al.Inflammatory cytokines in atherosclerosis:current therapeutic approaches.Eur Heart J, 6,7(22):1723-1732.
    [5] Evani SJ, Ramasubramanian AK.Biophysical regulation of Chlamydia pneumoniae-infected monocyte recruitment to atherosclerotic foci.Sci Rep, 6,6:19058.
    [6] Sessa R, Pietro MD, Filardo S, et al.Infectious burden and atherosclerosis:a clinical issue.World J Clin Cases, 4,2(7):240-249.
    [7] Shirai T, Hilhorst M, Harrison DG, et al.Macrophages in vascular inflammation--from atherosclerosis to vasculitis .Autoimmunity, 5,8(3):139-151.
    [8] Vaccarezza M, Balla C, Rizzo P.Atherosclerosis as an inflammatory disease:Doubts? No more.Int J Cardiol Heart Vasc, 8,9:1-2.
    [9] Sessa R, Pietro MD, Filardo S, et al.Infectious burden and atherosclerosis:a clinical issue.World J Clin Cases, 4,2(7):240-249.
    [10] Rojas M, Restrepo-Jimenez P, Monsalve DM, et al.Molecular mimicry and autoimmunity.J Autoimmun, 8,5:100-123.
    [11] Sima P, Vannucci L, Vetvicka V.Atherosclerosis as autoimmune disease.Ann Transl Med, 8,6(7):116.
    [12] Pothineni N, Subramany S, Kuriakose K, et al.Infections, atherosclerosis, and coronary heart disease.Eur Heart J, 7,8(43):3195-3201.
    [13] Zhu J, Quyyumi AA, Norman JE, et al.Effects of total pathogen burden on coronary artery disease risk and C-reactive protein levels.Am J Cardiol, 0,5(2):140-146.
    [14] Hartog L, van Rooijen MS, Ujcic-Voortman J, et al.Ethnic differences in infectious burden and the association with metabolic risk factors for cardiovascular disease:a cross-sectional analysis.BMC Public Health, 8,8(1):276.
    [15] Prochnau D, Straube E, Figulla HR, et al.Supra-additive expression of interleukin-6, interleukin-8 and basic fibroblast growth factor in vascular smooth muscle cells following coinfection with Chlamydia pneumoniae and cytomegalovirus as a novel link between infection and atherosclerosis.Can J Infect Dis Med Microbiol, 2,3(2):e26-e30.
    [16] O'Connor CM, Dunne MW, Pfeffer MA, et al.Azithromycin for the secondary prevention of coronary heart disease events:the WIZARD study:a randomized controlled trial.JAMA, 3,0(11):1459-1466.
    [17] Grayston JT, Kronmal RA, Jackson LA, et al.Azithromycin for the secondary prevention of coronary events.N Engl J Med, 5,2(16):1637-1645.
    [18] Cannon CP, Braunwald E, McCabe CH, et al.Antibiotic treatment of Chlamydia pneumoniae after acute coronary syndrome.N Engl J Med, 5,2(16):1646-1654.
    [19] Jespersen CM, Als-Nielsen B, Damgaard M, et al.Randomised placebo controlled multicentre trial to assess short term clarithromycin for patients with stable coronary heart disease:CLARICOR trial.BMJ, 6,2(7532):22-27.
    [20] Taleb S.Inflammation in atherosclerosis.Arch Cardiovasc Dis, 6,9(12):708-715.
    [21] Campbell LA, Rosenfeld ME, Persistent C.Pneumoniae infection in atherosclerotic lesions:rethinking the clinical trials.Front Cell Infect Microbiol, 4,4:34.
    [22] Beatty WL, Morrison RP, Byrne GI.Persistent chlamydiae:from cell culture to a paradigm for chlamydial pathogenesis.Microbiol Rev, 4,8(4):686-699.
    [23] Volkov AM, Murashov IS, Polonskaya YV, et al.Changes of content of matrix metalloproteinases and their tissue expression in various types of atherosclerotic plaques.Kardiologiia, 2018(10):12-18.
    [24] Newby AC.Dual role of matrix metalloproteinases (matrixins) in intimal thickening and atherosclerotic plaque rupture.Physiol Rev, 5,5(1):1-31.
    [25] Belo VA, Guimaraes DA, Castro MM.Matrix metalloproteinase 2 as a potential mediator of vascular smooth muscle cell migration and chronic vascular remodeling in hypertension.J Vasc Res, 5,2(4):221-231.
    [26] Kroon AM, Taanman JW.Clonal expansion of T cells in abdominal aortic aneurysm:a role for doxycycline as drug of choice?.Int J Mol Sci, 5,6(5):11178-11195.
    [27] Cid TP, Fernandez MC, Benito MS, et al.Pathogenesis of Helicobacter pylori infection.Helicobacter, 3,8(Suppl 1):12-17.
    [28] Hughes WS.An hypothesis:the dramatic decline in heart attacks in the United States is temporally related to the decline in duodenal ulcer disease and Helicobacter pylori infection.Helicobacter, 4,9(3):239-241.
    [29] Tobin NP, Henehan GT, Murphy RP, et al.Helicobacter pylori-induced inhibition of vascular endothelial cell functions:a role for VacA-dependent nitric oxide reduction.Am J Physiol Heart Circ Physiol, 8,5(4):H1403-H1413.
    [30] Corrado E, Rizzo M, Tantillo R, et al.Markers of inflammation and infection influence the outcome of patients with baseline asymptomatic carotid lesions:a 5-year follow-up study.Stroke, 6,7(2):482-486.
    [31] Blum A, Tamir S, Mualem K, et al.Endothelial dysfunction is reversible in Helicobacter pylori-positive subjects.Am J Med, 1,4(12):1171-1174.
    [32] Clar C, Oseni Z, Flowers N, etal.Influenza vaccines for preventing cardiovascular disease.Cochrane Database Syst Rev, 2015 (5):D5050.
    [33] Casscells SW, Granger E, Kress AM, et al.Use of oseltamivir after influenza infection is associated with reduced incidence of recurrent adverse cardiovascular outcomes among military health system beneficiaries with prior cardiovascular diseases.Circ Cardiovasc Qual Outcomes, 9,2(2):108-115.
    [34] Haidari M, Wyde PR, Litovsky S, et al.Influenza virus directly infects, inflames, and resides in the arteries of atherosclerotic and normal mice.Atherosclerosis, 0,8(1):90-96.
    [35] Smith SJ, Allen J, Blair SN, et al.AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease:2006 update:endorsed by the National Heart, Lung, and Blood Institute.Circulation, 6,3(19):2363-2372.
    [36] Olubamwo OO, Aregbesola AO, Miettola J, et al.Hepatitis C and risk of coronary atherosclerosisa systematic review.Public Health, 6,8:12-25.
    [37] Jung HJ, Kim YS, Kim SG, et al.The impact of pegylated interferon and ribavirin combination treatment on lipid metabolism and insulin resistance in chronic hepatitis C patients.Clin Mol Hepatol, 4,0(1):38-46.
    [38] Manigold T, Shin EC, Mizukoshi E, et al.Foxp3+CD4+CD25+ T cells control virus-specific memory T cells in chimpanzees that recovered from hepatitis C.Blood, 6,7(11):4424-4432.
    [39] Meissner EG, Lee YJ, Osinusi A, et al.Effect of sofosbuvir and ribavirin treatment on peripheral and hepatic lipid metabolism in chronic hepatitis C virus, genotype 1-infected patients.Hepatology, 5,1(3):790-801.
    Related
    Cited by
    Comments
    Comments
    分享到微博
    Submit
Get Citation

LIU Xufeng, MIN Xuchen, GU Xuefang, LI Gang. Relationship between anti-infective therapy and atherosclerosis[J]. Editorial Office of Chinese Journal of Arteriosclerosis,2020,28(5):452-455.

Copy
Share
Article Metrics
  • Abstract:1073
  • PDF: 785
  • HTML: 0
  • Cited by: 0
History
  • Received:July 23,2019
  • Revised:September 25,2019
  • Online: May 26,2020
Article QR Code

You are the 49975 visitor

Post Code：421001 Fax：0734-8160523

Phone：0734-8160765 E-mail：dmzzbjb@163.net

Editorial Office of Chinese Journal of Arteriosclerosis ® 2025